CVE:AQS Aequus Pharmaceuticals - AQS Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Aequus Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. C$0.03 -0.01 (-25.00%) (As of 03/16/2023) Add Compare Share Share Today's RangeC$0.03▼C$0.0350-Day RangeC$0.03▼C$0.0552-Week RangeC$0.02▼C$0.10Volume10,000 shsAverage Volume155,214 shsMarket CapitalizationC$3.98 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileChartCompetitorsEarningsInsider TradesHeadlines About Aequus Pharmaceuticals (CVE:AQS) StockAequus Pharmaceuticals Inc., a specialty pharmaceutical company, develops and commercializes drugs in Canada. It focuses on various therapeutic areas, including neurology, ophthalmology, and transplantation. The company markets Vistitan, an ophthalmology product to reduce elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Tacrolimus IR, an immunosuppressant for the treatment and prevention of acute rejection following organ transplantation; Evolve dry eye products for various symptoms involved with dry eye disease and blepharitis, including discomfort, stinging, burning, and dryness; and preservative free ophthalmic product. Its development stage product includes Topiramate XR and Oxcarbazepine XR extended-release oral tablets for the treatment of epilepsy; AQS1303, a transdermal pyridoxine/doxylamine for the treatment of nausea and vomiting of pregnancy; and AQS1304, a cannabinoid based therapeutics for neurological disorders. The company has collaboration agreements with Sandoz Canada, Inc. for the promotion of Vistitan; Supernus Pharmaceuticals, Inc. for marketing of extended-release anti-epileptic drugs; and Medicom Healthcare Ltd. to focus on preservative free therapies in ophthalmology. Aequus Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in Vancouver, Canada.Read More Receive AQS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aequus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address AQS Stock News HeadlinesDecember 20, 2022 | finance.yahoo.comAequus Announces Health Canada Notice of Compliance (NOC) for Zimed® Preservative Free (Bimatoprost 0.03%)November 30, 2022 | finanznachrichten.deAequus Pharmaceuticals: Aequus Reports Third Quarter 2022 Financial HighlightsMarch 21, 2023 | Weiss Ratings (Ad)Urgent WarningThis was never meant for the general public. But it’s all there in black and white … A frightening plan that gives the Fed the power to track and even control your checking account, including ALL your financial transactions. A pilot test program is already underway. And it’s slated to launch at America’s largest banks as soon as May of this year! So, time to prepare is very short. Fortunately, there are a few key steps you can take to defend yourself …November 30, 2022 | finance.yahoo.comAequus Reports Third Quarter 2022 Financial HighlightsNovember 29, 2022 | finance.yahoo.comAequus Announces Sandoz Contract Expiry at Year End and Expected Health Canada Approval for Zimed® PF (Preservative Free)October 9, 2022 | reuters.comAequus Pharmaceuticals IncAugust 30, 2022 | seekingalpha.comAequus Pharmaceuticals reports Q2 resultsAugust 29, 2022 | finance.yahoo.comAequus Reports Second Quarter 2022 Financial Highlights and General UpdateMarch 21, 2023 | Weiss Ratings (Ad)Urgent WarningThis was never meant for the general public. But it’s all there in black and white … A frightening plan that gives the Fed the power to track and even control your checking account, including ALL your financial transactions. A pilot test program is already underway. And it’s slated to launch at America’s largest banks as soon as May of this year! So, time to prepare is very short. Fortunately, there are a few key steps you can take to defend yourself …July 13, 2022 | finance.yahoo.comIIROC Trading Resumption - AQSJuly 13, 2022 | finance.yahoo.comAequus Resumes Trading on TSX Venture ExchangeMay 2, 2022 | finance.yahoo.comIIROC Trading Halt - AQS.WTMay 2, 2022 | finance.yahoo.comIIROC Trading Halt - AQS.DBApril 22, 2022 | benzinga.comAequus Announces Director ResignationJanuary 11, 2022 | finance.yahoo.comSandoz and Aequus Agree to 1-Year Extension on Vistitan in CanadaJanuary 6, 2022 | finance.yahoo.comAequus Announces Canadian Filing of NDS for Preservative-Free Glaucoma MedicationNovember 5, 2021 | ca.finance.yahoo.comIs Aequus Pharmaceuticals (CVE:AQS) Weighed On By Its Debt Load?August 25, 2021 | finance.yahoo.comAequus Strengthens Clinical Experience in Stargardt Disease with Pediatric Ophthalmology ExpertiseJuly 5, 2021 | finance.yahoo.comAEQUUS PHARMACEUTICALS INC (AQS.V) stock forecast and price targetJune 9, 2021 | proactiveinvestors.comAequus Pharmaceuticals says it will maintain commercial relationship with Sandoz into 2022June 9, 2021 | ca.finance.yahoo.comAequus Provides Commercial UpdateMay 31, 2021 | markets.businessinsider.comAequus Provides General Update and First Quarter 2021 Financial HighlightsApril 23, 2021 | benzinga.comAequus Provides General Update and Reports Record 2020 Financial ResultsApril 19, 2021 | markets.businessinsider.comAequus to Present at the 2021 Bloom Burton & Co. Healthcare Investor ConferenceApril 6, 2021 | proactiveinvestors.comAequus Pharmaceuticals receives $1.48 million from warrant acceleration exercisesApril 6, 2021 | finance.yahoo.comAequus Provides update on Warrant AccelerationMarch 1, 2021 | proactiveinvestors.comAequus Pharmaceuticals announces the commercial availability of Evolve preservative-free lubricating eye drops for dry eye careSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive AQS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aequus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address AQS Company Calendar Today3/20/2023Next Earnings (Estimated)3/21/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeCVE Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A SectorMedical Current SymbolCVE:AQS CUSIPN/A CIKN/A Webwww.aequuspharma.ca Phone+1-604-3367906FaxN/AEmployees10Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)C($0.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeC$-2,520,000.00 Net Margins-135.60% Pretax MarginN/A Return on Equity-291.74% Return on Assets-41.77% Debt Debt-to-Equity Ratio138.88 Current Ratio0.54 Quick Ratio0.46 Sales & Book Value Annual SalesC$1.86 million Price / Sales2.14 Cash FlowC$0.01 per share Price / Cash Flow5.00 Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares132,630,000Free FloatN/AMarket CapC$3.98 million OptionableNot Optionable Beta0.49 Key ExecutivesMr. Douglas Glen Janzen (Age 54)Chairman, CEO & Pres Comp: $225kMs. Ann Fehr CGA (Age 54)CPA, CFO & Corp. Sec. Comp: $155.94kMr. Stuart FowlerStrategic Commercial Advisor & Independent DirectorMr. Grant LarsenChief Commercial OfficerKey CompetitorsEve & Co IncorporatedCVE:EVELattice BiologicsCVE:LBLAcerus PharmaceuticalsTSE:ASPNeutriSci InternationalCVE:NUHarvest One CannabisCVE:HVTView All CompetitorsInsidersDoug JanzenBought 285,000 shares on 11/30/2022Total: C$11,400.00 ($0.04/share)Doug JanzenBought 115,000 shares on 11/20/2022Total: C$3,450.00 ($0.03/share)Marc LustigBought 64,000 shares on 7/25/2022Total: C$4,480.00 ($0.07/share)Marc LustigBought 4,000 shares on 7/21/2022Total: C$280.00 ($0.07/share)Doug JanzenBought 99,000 shares on 7/19/2022Total: C$6,930.00 ($0.07/share)View All Insider Transactions AQS Stock - Frequently Asked Questions How have AQS shares performed in 2023? Aequus Pharmaceuticals' stock was trading at C$0.04 at the beginning of 2023. Since then, AQS stock has decreased by 14.3% and is now trading at C$0.03. View the best growth stocks for 2023 here. When is Aequus Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 21st 2023. View our AQS earnings forecast. What other stocks do shareholders of Aequus Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aequus Pharmaceuticals investors own include GrowLife (PHOT), Unrivaled Brands (TRTC), Abbott Laboratories (ABT), Acorn Energy (ACFN), Crown Castle (CCI), Charlotte's Web (CWBHF), (FIRE.V) (FIRE), LiCo Energy Metals (LIC), Marijuana Company of America (MCOA) and Planet 13 (PLNHF). What is Aequus Pharmaceuticals' stock symbol? Aequus Pharmaceuticals trades on the Canadian Venture Exchange (CVE) under the ticker symbol "AQS." How do I buy shares of Aequus Pharmaceuticals? Shares of AQS stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. What is Aequus Pharmaceuticals' stock price today? One share of AQS stock can currently be purchased for approximately C$0.03. How much money does Aequus Pharmaceuticals make? Aequus Pharmaceuticals (CVE:AQS) has a market capitalization of C$3.98 million and generates C$1.86 million in revenue each year. The company earns C$-2,520,000.00 in net income (profit) each year or C($0.01) on an earnings per share basis. How can I contact Aequus Pharmaceuticals? Aequus Pharmaceuticals' mailing address is 2820-200 Granville St, VANCOUVER, BC V6C 1S4, Canada. The official website for the company is www.aequuspharma.ca. The company can be reached via phone at +1-604-3367906. This page (CVE:AQS) was last updated on 3/21/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.